Download PDF
Pharmacopsychiatry 2006; 39(5): 161-170
DOI: 10.1055/s-2006-949513
Review

© Georg Thieme Verlag KG Stuttgart · New York

The Concepts of Remission and Recovery in Schizophrenia

S. Leucht 1 , R. Lasser 2
  • 1Department of Psychiatry, Technische Universität München, Munich, Germany
  • 2Comprehensive Neuroscience White Plains, New York, USA
Further Information

Publication History

Received 9.1.2006 Revised 6.6.2006

Accepted 6.6.2006

Publication Date:
30 August 2006 (online)

Also available at
    Permissions and Reprints

Objective: To examine the past and current research into the concepts of remission and recovery in schizophrenia. Data Sources: An electronic literature search of studies published between January 1990-April 2005 examining the concepts of remission and recovery in schizophrenia and the treatment of schizophrenia with antipsychotic agents was performed using Medline and EMBASE. Primary research parameters were ‘schizophrenia’, ‘remission’, ‘recovery’, ‘meta-analysis’, ‘antipsychotics’, ‘atypicals’, ‘conventional’, ‘cognition’, ‘function’ and ‘quality of life’. Study selection: English language articles, original research articles, reviews and other articles of interest were reviewed. Data extraction: Data quality was determined by publication in the peer-reviewed literature and the most important information was identified. Data synthesis: A number of different definitions of remission and recovery have been previously used, which has made comparison of study results problematic. Recently, the first operational definition of remission, based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria (DSM-IV) for schizophrenia, was developed. It is hoped that this will provide a standard tool for assessing the effectiveness of treatments for schizophrenia. Recovery, which encompasses both symptom remission and more functional aspects of patient's well being, such as cognition, social functionality and quality of life, is still to be satisfactorily defined. Although recent studies on new generation antipsychotics have examined some proxy outcomes related to recovery, further research is required. Conclusions: Until the definition for ‘recovery’ is further elucidated, factors such as symptom control and remission, and functional aspects of recovery such as improvements in cognition and social functioning, which are quantifiable, should be used as measures of treatment outcome and markers of recovery.

References

  • 1 Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Emst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis.  Eur Child Adolesc Psychiatry. 1997;  6 212-218
    PubMedGoogle Scholar
  • 2 Andreasen N, Carpenter W, Kane J, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus.  Am J Psychiatry. 2005;  162 441-449
    CrossrefPubMedGoogle Scholar
  • 3 Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model.  Aust N Z J Psychiatry. 2003;  37 586-594
    CrossrefPubMedGoogle Scholar
  • 4 Angermeyer MC, Kuhn L, Goldstein JM. Gender and course of schizophrenia: differences in treated outcomes.  Schizophr Bull. 1990;  16 293-307
    PubMedGoogle Scholar
  • 5 Auslander LA, Jeste DV. Sustained remission of schizophrenia among community-dwelling older outpatients.  Am J Psychiatry. 2004;  161 1490-1493
    CrossrefPubMedGoogle Scholar
  • 6 Bouchard RH, Merette C, Pourcher E, Demers MF, Villenueve J, Roy-Gagnon MH. et al . Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group.  J Clin Psychopharmacol. 2000;  20 295-304
    CrossrefPubMedGoogle Scholar
  • 7 Brenner H, Dencker S, Goldstein M, Hubbard JW, Keegan DL, Kruger J. et al . Defining treatment refractoriness in schizophrenia.  Schizoph Bull. 1990;  16 551-561
    PubMedGoogle Scholar
  • 8 Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics.  Schizophr Bull. 1980;  6 606-618
    PubMedGoogle Scholar
  • 9 Cohen D. Atypical antipsychotics and new onset diabetes mellitus: An overview of the literature.  Pharmcopsychiatry. 2004;  37 1-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Cole JO. Evaluation of drug treatments in psychiatry.  Proc Annu Meet Am Psychopathol Assoc. 1964;  52 14-31
    PubMedGoogle Scholar
  • 11 Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.  Int Clin Psychopharmacol. 2000;  15 13-22
    PubMedGoogle Scholar
  • 12 Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry. 2004;  161 414-425
    CrossrefPubMedGoogle Scholar
  • 13 Curtis CE, Calkins ME, Lacono WG. Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. A parametric study of the effects of increasing inhibitory load.  Exp Brain Res. 2001;  137 228-236
    CrossrefPubMedGoogle Scholar
  • 14 Davis J, Matalon L, Watanabe M, Blake L. Depot antipsychotic drugs. Place in therapy.  Drugs. 1994;  47 741-773
    CrossrefPubMedGoogle Scholar
  • 15 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics.  Arch Gen Psychiatry. 2003;  60 553-564
    CrossrefPubMedGoogle Scholar
  • 16 Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents?.  Am J Psychiatry. 2002;  159 103-108
    CrossrefPubMedGoogle Scholar
  • 17 Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders.  J Clin Psychiatry. 2003;  64 ((Suppl 15)) 40-45
    PubMedGoogle Scholar
  • 18 Eaton WW, Thara R, Federman E, Tien A. Remission and relapse in schizophrenia: the Madras Longitudinal Study.  J Nerv Ment Dis. 1998;  186 357-363
    CrossrefPubMedGoogle Scholar
  • 19 Ferrier IN. Characterizing the ideal antidepressant therapy to achieve remission.  J Clin Psychiatry. 2001;  62 ((Suppl 26)) 10-15
    Google Scholar
  • 20 Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence.  Arch Gen Psychiatry. 1991;  48 851-855
    CrossrefPubMedGoogle Scholar
  • 21 Freedman R. Schizophrenia.  N Engl J Med. 2003;  349 1738-1749
    CrossrefPubMedGoogle Scholar
  • 22 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  BMJ. 2000;  321 1371-1376
    CrossrefPubMedGoogle Scholar
  • 23 Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention.  Acta Psychiatr Scand Suppl. 1994;  382 28-32
    PubMedGoogle Scholar
  • 24 Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.  J Clin Psychiatry. 2003;  64 119-122
    PubMedGoogle Scholar
  • 25 Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DC. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.  Biol Psychiatry. 2002;  51 972-978
    CrossrefPubMedGoogle Scholar
  • 26 Green MF, Marshall JrBD, Wirshing WC, Ames D, Marder SR, McGurk S. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?.  Am J Psychiatry. 1997;  154 799-804
    PubMedGoogle Scholar
  • 27 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiatry. 1960;  23 56-62
    CrossrefPubMedGoogle Scholar
  • 28 Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia.  Am J Psychiatry. 1987;  144 727-735
    PubMedGoogle Scholar
  • 29 Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J. Recovery from psychotic illness: a 15- and 25-year international follow-up study.  Br J Psychiatry. 2001;  178 506-517
    CrossrefPubMedGoogle Scholar
  • 30 Hartung B, Wada M, Laux G. et al . Perphenazine for schizophrenia.  Cochrane Database Syst Rev. 2005;  25 CD003443
    PubMedGoogle Scholar
  • 31 Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.  Am J Psychiatry. 2000;  157 808-815
    CrossrefPubMedGoogle Scholar
  • 32 Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients.  Schizophr Bull. 1980;  6 592-605
    CrossrefPubMedGoogle Scholar
  • 33 Keefe RS, Silva SG, Perkins DO. et al . The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.  Schizophr Bull. 1999;  25 201-222
    PubMedGoogle Scholar
  • 34 Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentration by sex in a fixed-dose study.  Schizophr Res. 1999;  40 101-104
    PubMedGoogle Scholar
  • 35 Kraepelin E. Dementia Praecox and Paraphrenia. Translated and edited by RB Barclay. Edinburgh; ES Livingston 1919
    Google Scholar
  • 36 Lambert M, Schimmelmann B, Karow A. et al . Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical review.  Pharmacopsychiatry. 2003;  36 181-190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Larsen NE, Hansen LB. Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks.  ThermDrug Monit. 1989;  11 642-646
    PubMedGoogle Scholar
  • 38 Lasser R, Bossie C, Gharabawi G, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.  Int J Neuropsychopharmacol. 2005;  8 1-12
    CrossrefPubMedGoogle Scholar
  • 39 Lasser R, Bossie C, Gharabawi G, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone.  Eur Psychiatry. 2004;  19 219-225
    CrossrefPubMedGoogle Scholar
  • 40 Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.  Schizophr Res. 2005;  77 215-227
    CrossrefPubMedGoogle Scholar
  • 41 Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.  Am J Psychiatry. 2003;  160 1209-1222
    Google Scholar
  • 42 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.  Schizophr Res. 1999;  35 51-68
    CrossrefPubMedGoogle Scholar
  • 43 Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.  Lancet. 2003;  361 1581-1589
    CrossrefPubMedGoogle Scholar
  • 44 Leucht S, Pitschel-Walz G, Engel RR. et al . Amisulpride, an unsual atypical antipsychotic: a meta-analysis of randomised controlled trials.  Am J Psychiatry. 2002;  159 180-190
    CrossrefPubMedGoogle Scholar
  • 45 Liberman R, Kopelowicz A, Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia.  Int Rev Psychiatry. 2002;  14 256-272
    CrossrefPubMedGoogle Scholar
  • 46 Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S. Time course and biologic correlates of treatment response in first-episode schizophrenia.  Arch Gen Psychiatry. 1993;  50 369-376
    PubMedGoogle Scholar
  • 47 Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine.  Neuropsychopharmacology. 2003;  28 995-1003
    PubMedGoogle Scholar
  • 48 Lieberman JA, Stroip TS, McEvoy. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
    CrossrefPubMedGoogle Scholar
  • 49 Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.  J Clin Psychiatry. 2004;  65 1084-1089
    CrossrefPubMedGoogle Scholar
  • 50 Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia.  Am J Psychiatry. 1992;  149 1183-1188
    PubMedGoogle Scholar
  • 51 Meltzer HY, Burnett S, Bastani B, Ramirez LF. Cognitive factors in schizophrenia: causes, impact, and treatment.  CNS Spectr. 2004;  9 ((10 Suppl 11)) 15-24
    PubMedGoogle Scholar
  • 52 Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.  Biol Psychiatry. 2004;  55 1013-1022
    Google Scholar
  • 53 Molina V, Sanz J, Sarramea F, Benito C, Palomo T. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients.  Psychiatry Res. 2004;  131 45-56
    PubMedGoogle Scholar
  • 54 Muller N. Mechanisms of relapse prevention in schizophrenia.  Pharmacopsychiatry. 2004;  37 141-147
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.  Int Clin Psychopharmacol. 1995;  10 ((Suppl 3)) 133-138
    CrossrefPubMedGoogle Scholar
  • 56 Nasrallah H, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life with schizophrenia during treatment with long-acting risperidone injection.  J Clin Psychiatry. 2004;  65 531-536
    CrossrefPubMedGoogle Scholar
  • 57 Ogawa K, Miya M, Watarai A, Nakazawa M, Yuasa S, Utena H. A long-term follow-up study of schizophrenia in Japan with special reference to the course of social adjustment.  Br J Psychiatry. 1987;  151 758-765
    PubMedGoogle Scholar
  • 58 Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia.  Am J Psychiatry. 1996;  153 607-617
    PubMedGoogle Scholar
  • 59 Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley Jr CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.  Qual Life Res. 1999;  8 417-426
    CrossrefPubMedGoogle Scholar
  • 60 Robinson DG, Woerner MG, McMeniman, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2004;  161 473-479
    CrossrefPubMedGoogle Scholar
  • 61 Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.  N Engl J Med. 1997;  337 809-815
    CrossrefPubMedGoogle Scholar
  • 62 Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - A randomized controlled trial.  JAMA. 2003;  290 2693-2702
    CrossrefPubMedGoogle Scholar
  • 63 Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G. Risperdione and haloperidol in first-episdoe psychosis: a long-term randomsied trial.  Am J Psychiatry. 2005;  162 947-953
    Google Scholar
  • 64 Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.  Am J Psychiatry. 2002;  159 561-566
    CrossrefPubMedGoogle Scholar
  • 65 Sethuraman G, Taylor CC, Enerson M, Dunayevich E. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.  Schizophr Res. 2005;  79 337-340
    CrossrefPubMedGoogle Scholar
  • 66 Tollefson GD. Cognitive function in schizophrenic patients.  J Clin Psychiatry. 1996;  57 ((Suppl 11)) 31-39
    PubMedGoogle Scholar
  • 67 Turkoz I, Lasser R, Rodriguez S, Locklear J, Mahableshwarkar A, Gharabawi G. Functioning and quality of life during long-acting risperidone maintenance treatment. In: American Psychiatric Association, May 22-26 2005 Atlanta, USA; Abstract N205
    Google Scholar
  • 68 Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.  J Clin Psychiatry. 2001;  62 545-551
    PubMedGoogle Scholar
  • 69 van Os J, Bossie C, Lasser R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.  Int Clin Psychopharmacol. 2004;  19 229-232
    CrossrefPubMedGoogle Scholar
  • 70 Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia.  Schizophr Res. 1997;  25 21-31
    CrossrefPubMedGoogle Scholar
  • 71 Wahlbeck K, Cheine M, Essali A. et al . Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomised trials.  Am J Psychiatry. 1999;  156 990-999
    PubMedGoogle Scholar
  • 72 Weiden P, Zygmunt A. Medication noncompliance in schizophrenia. Part I. Assessment.  J Prac Psychiatry Behav Health. 1997;  3 106-110
    PubMedGoogle Scholar
  • 73 Weiss U, Marksteiner J, Kemmler G. et al . Effects of age and sex on olanzapine plasma concentrations.  J Clin Psychopharmacol.. 2005;  25 570-574
    CrossrefPubMedGoogle Scholar
  • 74 Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.  Int J Neuropsychopharmacol. 2005;  8 457-472
    CrossrefPubMedGoogle Scholar
  • 75 Wyatt R. Neuroleptics and the natural course of schizophrenia.  Schizophr Bull. 1991;  17 325-351
    PubMedGoogle Scholar
  • 76 Yen CF, Chen CS, Yeh ML, Yen JY, Ker JH, Yang SJ. Comparison of insight in patients with schizophrenia and bipolar disorder in remission.  J Nerv Ment Dis. 2002;  190 847-849
    CrossrefPubMedGoogle Scholar
  • 77 Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia.  Am J Psychiatry. 2002;  159 1653-1664
    Google Scholar

Correspondence

PD Dr. med. Stefan LeuchtMD 

Department of Psychiatry and Psychotherapy·Technische Universität München

Ismaningerstr. 22·81675 Munich·Germany

Phone: +49/89/4140 42 49

Fax: +49/89/4140 48 88

Email: Stefan.Leucht@Lrz.tu-muenchen.de

      >